research A comparative study on therapeutic efficacy between topical dinitrochlorobenzene and topical betamethasone in alopecia areata
DNCB is more effective than betamethasone for hair regrowth but has more side effects.
Search
for
Sort by
Research
240-270 / 1000+ results 
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research [Treatment of moderately severe virilism of women with Diane and Androcur 10].
Diane and Androcur 10 improved acne and seborrhea in most women, and hirsutism and alopecia in about half.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level
Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
research Profile of the progesterone derivative chlormadinone acetate — Pharmocodynamic properties and therapeutic applications
Chlormadinone acetate is a strong, well-tolerated hormone used in birth control and hormone therapy with benefits for menstrual pain and skin conditions.
research Terazosin or baclofen in young men with chronic orchialgia: A cohort study of 499 patients
Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.
research Latanoprost
research Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
Bicalutamide may be a promising alternative treatment for female pattern hair loss.
research Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research Efficacy of Letrozole (LE) Combined with Cabergoline (CE) in Comparison to LE alone in ovulation induction among patients with Polycystic Ovarian Syndrome (PCOS) and Hyperprolactinemia (HP)
Letrozole combined with Cabergoline improves ovulation and pregnancy rates in women with PCOS and high prolactin levels compared to Letrozole alone.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
The birth control combination of ethinylestradiol and drospirenone helps treat symptoms of polycystic ovary syndrome.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research SAT-435 When The Cure Becomes The Cause: Adrenal Insufficiency In Cushing’s Management
Careful dosing and monitoring are crucial to prevent adrenal insufficiency when using ketoconazole for Cushing's disease.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
research Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Fadrozole and finasteride exposures modulate sex steroid- and thyroid hormone-related gene expression in Silurana (Xenopus) tropicalis early larval development
Fadrozole and finasteride change gene expression related to sex hormones and thyroid hormones in frog larvae development.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.